Skip to content

Study · Observational study · n = 26 · 2025

6 results

Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.

Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN

Journal of diabetes science and technology5 Feb 2024Cited by 46 (Europe PMC)

PMID38317405 (opens in a new tab)PMCIDPMC11571402 (opens in a new tab)DOI10.1177/19322968231223991 (opens in a new tab)PepBankPUB-38317405
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 1 diabetes, tirzepatide was associated with a significant HbA1c reduction of 0.45% at 3 months and 0.59% at 8 months.

    In plain wordsIn adults with type 1 diabetes, HbA1c fell after starting tirzepatide, by 0.59% at 8 months, in a study with no control group.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c reduction
    Study

    n = 26

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 8 monthsAs given in this study (human).

    Measurements

    HbA1c reduction
    0.45%
    3 months
    HbA1c reduction
    0.59%
    8 months

    Source sentences

    Summary
    There was significant reduction in HbA1c by 0.45% at 3 months and 0.59% at 8 months
    2 context sentences
    Summary · context
    In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months.
    Summary · context
    The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m2.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 1 diabetes, body weight fell significantly by 3.4%, 10.5% and 10.1% at 3, 6 and 8 months after starting tirzepatide.

    In plain wordsIn adults with type 1 diabetes, body weight fell by 10.5% at 6 months after starting tirzepatide, in a study with no control group.

    Peptide
    Tirzepatide
    Outcome
    DecreasePercent body weight change
    Study

    n = 26

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 8 monthsAs given in this study (human).

    Measurements

    Body weight reduction
    3.4%
    3 months
    Body weight reduction
    10.5%
    6 months
    Body weight reduction
    10.1%
    8 months

    Source sentences

    Summary
    and a significant reduction in body weight by 3.4%, 10.5%, and 10.1% at 3, 6, and 8 months after starting tirzepatide.
    2 context sentences
    Summary · context
    In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months.
    Summary · context
    The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m2.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 1 diabetes, time in target range increased by 12.6% at 3 months after starting tirzepatide, and the change was sustained over 8 months.

    In plain wordsIn adults with type 1 diabetes, time spent in the target glucose range rose after starting tirzepatide, in a study with no control group.

    Peptide
    Tirzepatide
    Outcome
    IncreaseCGM time in target range (70-180 mg/dL)
    Study

    n = 26

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 8 monthsAs given in this study (human).

    Measurements

    Time in range change
    12.6%
    3 months

    Source sentences

    Summary
    Time in target range (TIR = 70-180 mg/dL) and time in tight target range (TITR = 70-140 mg/dL) increased (+12.6%, P = .002; +10.7%, P = .0016, respectively) and time above range (TAR >180 mg/dL) decreased (-12.6%, P = .002) at 3 months, and these changes were sustained over 8 months.
    2 context sentences
    Summary · context
    In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months.
    Summary · context
    The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m2.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 1 diabetes, time in tight target range increased by 10.7% at 3 months after starting tirzepatide, and the change was sustained over 8 months.

    In plain wordsIn adults with type 1 diabetes, time spent in the tight glucose range rose after starting tirzepatide, in a study with no control group.

    Peptide
    Tirzepatide
    Outcome
    IncreaseCGM time in tight target range (70-140 mg/dL)
    Study

    n = 26

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 8 monthsAs given in this study (human).

    Measurements

    Time in tight range change
    10.7%
    3 months

    Source sentences

    Summary
    Time in target range (TIR = 70-180 mg/dL) and time in tight target range (TITR = 70-140 mg/dL) increased (+12.6%, P = .002; +10.7%, P = .0016, respectively) and time above range (TAR >180 mg/dL) decreased (-12.6%, P = .002) at 3 months, and these changes were sustained over 8 months.
    2 context sentences
    Summary · context
    In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months.
    Summary · context
    The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m2.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 1 diabetes, time above range decreased by 12.6% at 3 months after starting tirzepatide, and the change was sustained over 8 months.

    In plain wordsIn adults with type 1 diabetes, time spent with high glucose fell after starting tirzepatide, in a study with no control group.

    Peptide
    Tirzepatide
    Outcome
    DecreaseCGM time above range (>180 mg/dL)
    Study

    n = 26

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 8 monthsAs given in this study (human).

    Measurements

    Time above range change
    −12.6%
    3 months

    Source sentences

    Summary
    Time in target range (TIR = 70-180 mg/dL) and time in tight target range (TITR = 70-140 mg/dL) increased (+12.6%, P = .002; +10.7%, P = .0016, respectively) and time above range (TAR >180 mg/dL) decreased (-12.6%, P = .002) at 3 months, and these changes were sustained over 8 months.
    2 context sentences
    Summary · context
    In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months.
    Summary · context
    The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m2.
  6. 06HumanObservational studySafety outcome

    In adults with type 1 diabetes, tirzepatide was reported as relatively safe and well tolerated, with only 2 patients discontinuing the medication.

    In plain wordsIn adults with type 1 diabetes, only 2 of 26 patients stopped tirzepatide, and the drug was reported as relatively safe.

    Peptide
    Tirzepatide
    Outcome
    Not applicableTreatment discontinuation
    Study

    n = 26

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 8 monthsAs given in this study (human).

    Source sentences

    Summary
    The drug was relatively safe and well tolerated with only 2 patients discontinuing the medication.
    2 context sentences
    Summary · context
    In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months.
    Summary · context
    The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.